NTRA — Natera, Inc.

Natera (NTRA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $666 million in Q4 2025, representing a 40% year-over-year growth and exceeding pre-announced expectations by $6 million.
• Tests Processed: Approximately 924,000 tests, with 225,000 MRD clinical tests, marking a 56% increase from Q4 2024.
• Gross Margin: 66.9% for Q4, with an organic gross margin of 63.7% after accounting for revenue true-ups.
• Cash Flow: Generated over $107 million in cash flow for 2025.
• Accounts Receivable: Days Sales Outstanding (DSO) improved to 47 days from 68 days in Q4 2024.
• Operating Losses: Narrowed significantly, with net income reported in Q4 due to a one-time deferred tax item.

2. Strategic Updates and Business Highlights:

• Product Launches: Introduced the 21-gene Fetal Focus single-gene NIPT test and expanded the MRD portfolio with the genome version of Signatera and Latitude tests.
• Clinical Advancements: The Latitude Tissue-Free MRD test was submitted to MolDx; Fetal Focus received recognition at the Society of Maternal-Fetal Medicine Conference.
• Market Adoption: Over 50% of U.S. oncologists ordered Signatera tests, indicating strong integration into standard cancer care.
• Partnerships and Acquisitions: Welcomed Foresight Diagnostics, enhancing capabilities in ultrasensitive MRD testing.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to generate between $2.62 billion and $2.7 billion, with gross margins projected between 63% and 65%.
• Investment Strategy: Plans to maintain stable SG&A while increasing R&D investments, particularly in clinical trials and product development.
• Volume Growth: Anticipates continued strong growth in oncology, women's health, and organ health segments.

4. Bad News, Challenges, or Points of Concern:

• Reimbursement Risks: Some tests remain in non-covered indications, which could impact ASPs and revenue growth.
• Market Competition: Increasing competition in the MRD testing space could pressure pricing and market share.
• Operational Challenges: While the company is focused on margin expansion, some improvements seen in Q4 may not be sustainable every quarter.

5. Notable Q&A Insights:

• Signatera ASPs: Changes in Medicare reimbursement could offset each other, with potential upside from broader coverage decisions.
• Market Share in Women's Health: Natera is seeing growth in women's health, particularly with the new Fetal Focus test, although overall market share data is not available.
• Hematology Opportunities: Current contributions from lymphoma and multiple myeloma are limited, but seen as significant growth opportunities in the future.
• Japan Market Entry: Anticipated approval for Signatera in Japan in 2026, with a strong potential for ASPs similar to the U.S. market.
• Operational Efficiency: The company aims to maintain flat SG&A expenses while driving revenue growth through a well-prepared sales force and improved operational leverage.

Overall, Natera demonstrated strong financial performance and strategic advancements in Q4 2025, with a positive outlook for 2026, although challenges in reimbursement and competitive pressures remain.